inclisiran
Sponsor Novartis AG · listed as NVS
inclisiran is a drug asset sponsored by Novartis AG, listed as NVS. CSA tracks 4 forward catalysts for it — the nearest is a readout expected Oct 26, 2026 (day precision, medium confidence), tied to trial NCT05360446. That trial is in Phase 3 and currently active not recruiting, studying Coronary Artery Disease. It appears across 9 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
All tracked catalysts for inclisiran
| Date | Event | Confidence | Trial |
|---|---|---|---|
| 2026-10-26 | READOUT | medium | NCT05360446 |
| 2027-02-11 | READOUT | medium | NCT07102628 |
| 2027-05-10 | READOUT | medium | NCT05030428 |
| 2028-03-21 | READOUT | medium | NCT06597006 |
Trials for inclisiran in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT04765657 | Phase 3 | Active, not recruiting | 2022-06-09 | Experimental | Novartis Pharmaceuticals | Hypercholesterolemia |
| NCT03705234 | Phase 3 | Active, not recruiting | 2026-10 | Experimental | University of Oxford | Atherosclerotic Cardiovascular Disease |
| NCT05360446 catalyst | Phase 3 | Active, not recruiting | 2026-10-26 | Experimental | Novartis Pharmaceuticals | Coronary Artery Disease |
| NCT07102628 catalyst | Phase 3 | Recruiting | 2027-02-11 | Experimental | Novartis Pharmaceuticals | Acute Coronary Syndrome |
| NCT05030428 catalyst | Phase 3 | Active, not recruiting | 2027-05-10 | Experimental | Novartis Pharmaceuticals | Atherosclerotic Cardiovascular Disease |
| NCT06813911 | Phase 3 | Recruiting | 2028-02-03 | Active comparator | Novartis Pharmaceuticals | Atherosclerotic Cardiovascular Disease (ASCVD) |
| NCT06597006 catalyst | Phase 3 | Recruiting | 2028-03-21 | Experimental | Novartis Pharmaceuticals | Familial Hypercholesterolemia - Homozygous |
| NCT06597019 | Phase 3 | Recruiting | 2028-03-21 | Experimental | Novartis Pharmaceuticals | Familial Hypercholesterolemia - Heterozygous |
| NCT05682378 | Phase 3 | Recruiting | 2032-03-25 | Experimental | Novartis Pharmaceuticals | Heterozygous or Homozygous Familial Hypercholesterolemia |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More NVS catalysts